A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 150 participants.

Also called NCT07724340

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 150 participants (planned count) (from the registry)
Sponsor
Antag Therapeutics (from the registry)
Registry
  • NCT NCT07724340
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT07724340. Randomized; double masking; primary purpose treatment. Start 2026-06-19 (actual); primary completion 2027-02 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity
Condition
Adults With Overweight/Obesity and Type 2 Diabetes
Intervention (Drug)
AT673 low dose
Intervention (Drug)
AT673 high dose
Intervention (Drug)
Placebo
Lead sponsor
Antag Therapeutics (class: industry)

Record details

Record id
cardio:ct-nct07724340
Content hash
c3cba921307dbcb5dcf02a0e641bb3a7a345262c999ae8ca13dceecbdc0bcf90